+0.01 (+0.25%)
Dilution Risk
Revenue
1.03 M
R&D Expenses
2.87 M
Operating CF
-6.24 M
Total Assets
19.92 M
Total Liabilities
7.96 M
Equity
11.96 M
D/E Ratio
12,345
Cash Position
15.11 M
Monthly Burn
2.08 M
Runway
5.7 mo
Burn Trend
SEC Filing
May 15, 2026locked
| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Radiopharmaceuticals | Oncology | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Radiopharmaceuticals | Oncology | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Radiopharmaceuticals | Oncology |
Dated clinical, regulatory & corporate events for PLUS THERAPEUTICS, Inc.
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| apatinib Small molecule | Colorectal Neoplasms | Phase 2 | NCT03190616 | 19% | $516M | COMPLETED | 54 | - | - | Dec 30, 2019 | - | Jan 14, 2020 |
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
REYOBIQ Orphan | leptomeningeal metastases | Phase 1 | 2026-05-08 | median overall survival: approximately 9 months; historical survival: approximately 2–6 months; target to off target ratio: exceeding 100:1 Read More | Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases Read More | |
REYOBIQ Orphan | leptomeningeal metastases | Phase 1 | 2026-05-08 | median overall survival: approximately 9 months; historical survival: approximately 2–6 months; target to off target ratio: exceeding 100:1 Read More | Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases Read More | |
REYOBIQ Orphan | leptomeningeal metastases | Phase 1 | 2026-05-08 | median overall survival: approximately 9 months; historical survival: approximately 2–6 months; target to off target ratio: exceeding 100:1 Read More | Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases Read More |
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Plus Therapeutics, soon to be Cerenome, is set to change its Nasdaq ticker to CNSY on August 3, 2026. The company affirmed its 2026 milestones, reporting positive progress in its CNSide diagnostics and REYOBIQ therapeutic developments. A business update conference call will provide further insights into the rebranding and ongoing projects.
Read more →Plus Therapeutics, through its subsidiary CNSide Diagnostics, has secured a national coverage agreement with Elevance Health for its CNSide® Cerebrospinal Fluid Tumor Cell Enumeration assay. This agreement, effective May 1, 2026, extends coverage to approximately 45.4 million people, enhancing the total coverage to 126 million. The CNSide assay has demonstrated superior clinical utility and has been pivotal in treatment decision-making for patients with leptomeningeal metastases.
Read more →Plus Therapeutics announced a business update call scheduled for June 30, 2026, focusing on their CNSide diagnostic launch and the development of their lead drug, Reyobiq. The call will also cover the company's strategy in CNS oncology and advancements in artificial intelligence. CEO Marc H. Hedrick expressed optimism about the company's progress in diagnostics, therapeutics, and AI.
Read more →Plus Therapeutics' subsidiary, CNSide Diagnostics, has achieved accreditation from the College of American Pathologists (CAP) for its clinical laboratory in Houston. This accreditation recognizes the laboratory's quality and operational standards, bolstering its position in the CNS cancer diagnostics market. It is anticipated to enhance payor engagement and expand the adoption of the CNSide® CSF Assay Platform, which assists in diagnosing leptomeningeal metastases. The achievement marks a significant milestone in CNSide Diagnostics' commitment to excellence in healthcare.
Read more →Plus Therapeutics has announced promising findings for its CNSide diagnostic platform, focusing on leptomeningeal metastases. The study, presented at the ISPOR 2026 Annual Meeting, indicates that early detection and therapeutic management can lead to a healthcare cost reduction of 33-47%. The company's analysis highlights the financial burden of late-stage LM diagnosis and the cost-saving potential of timely interventions. CNSide, aimed at improving outcomes in patients with CNS cancers, continues to gain recognition within healthcare economics and decision-making circles.
Read more →Plus Therapeutics has partnered with Ephemeral Technologies to create an AI execution platform aimed at enhancing CNS oncology. This platform will integrate and analyze proprietary data to improve precision in treatment and diagnostics. The collaboration is expected to boost operational efficiency and support the development of targeted therapies for CNS cancers.
Read more →Plus Therapeutics reported its Q1 2026 financial results, highlighting significant advancements in its REYOBIQ clinical program and CNSide commercial rollout. The company achieved FDA Orphan Drug Designation for REYOBIQ and expanded payer coverage for CNSide diagnostics. Despite an operating loss of $7.1 million, the company remains focused on its 2026 milestones.
Read more →Plus Therapeutics presented positive data from the Phase 1 ReSPECT-LM trial of REYOBIQ at the AANS Annual Scientific Meeting. The trial showed encouraging survival outcomes and robust anti-tumor activity in patients with leptomeningeal metastases. The presentation highlighted the drug's favorable safety profile and potential for immune modulation, supporting its advancement in clinical development.
Read more →The article discusses the integration of diagnostics and targeted radiation therapy in brain cancer care. It emphasizes the importance of combining these approaches to improve patient outcomes. However, specific details about advancements or studies are not provided in the text.
Read more →Plus Therapeutics, Inc. announced that its subsidiary, CNSide Diagnostics, has achieved Medicare enrollment, allowing the submission of claims for its CNSide® CSF Assay Platform. This significant step in commercialization will enable billing to the Medicare population, increasing patient access and aiding in revenue growth. The company is now set to engage with Medicare Administrative Contractors for coverage determinations and expand its payer contracts to increase coverage. The CNSide® platform enhances diagnostic capabilities for CNS cancers, leading to better patient management.
Read more →The article discusses advancements in precision radiotherapeutics aimed at treating challenging central nervous system (CNS) cancers. It highlights the importance of targeted therapies in improving treatment outcomes for patients with these difficult-to-treat conditions. The focus is on innovative approaches that could enhance the efficacy of radiotherapy.
Read more →The article discusses an interview with PSTV on Nasdaq, focusing on their market movements. However, the content primarily revolves around cookie consent and website privacy policies rather than specific insights about PSTV's performance or strategic direction.
Read more →Plus Therapeutics has secured a coverage agreement with Blue Shield of California for its CNSide® Cerebrospinal Fluid assay, effective April 2026. This agreement increases the total covered lives for CNSide from approximately 75 million to 81 million, supporting the company's goal of reaching 150 million covered lives by 2026. The CNSide assay offers improved detection and monitoring of leptomeningeal metastases, which may enhance patient outcomes.
Read more →Plus Therapeutics has initiated manufacturing activities with SpectronRx to support the late-stage clinical manufacturing of REYOBIQ and Rhenium-186. This collaboration aims to enhance the reliability of the supply chain and improve coordination in radiopharmaceutical production. The company is focused on meeting its 2026 milestone for manufacturing scale-up for REYOBIQ, which targets CNS cancers.
Read more →Plus Therapeutics, Inc. has announced the granting of inducement awards to its new Chief Development Officer, Dr. Eric J Daniels. The awards include options to purchase 20,000 shares of common stock and 20,000 restricted stock units, incentivizing Dr. Daniels' employment with the company. The inducement awards adhere to Nasdaq Rule 5635(c)(4) and are intended to bolster the company's leadership as it continues to develop targeted radiotherapeutics for CNS cancers.
Read more →Plus Therapeutics, Inc. has confirmed its compliance with Nasdaq's minimum bid price requirement after maintaining a closing bid price above $1.00 for 10 consecutive business days. This notification from Nasdaq indicates that the compliance issue is now resolved. The company continues to develop targeted radiotherapeutics for CNS cancers.
Read more →The article discusses a Boardroom Exclusive interview with Dr. Marc Hedrick, focusing on insights and updates related to PSTV. However, the content primarily revolves around website cookie policies and does not provide substantial information about the interview or its implications for the company.
Read more →Plus Therapeutics has appointed Dr. Randy H. Goodman as Vice President of Value Strategy & HEOR, effective April 13, 2026. Dr. Goodman brings over 20 years of experience in health economics, market access, and health policy, which the company expects will be invaluable in expanding access to its CNSide Diagnostics and advancing its oncology pipeline. He has previously advised numerous high-profile healthcare organizations and government agencies, positioning him to enhance Plus Therapeutics' approach to demonstrating the value of its technologies.
Read more →Plus Therapeutics has appointed Dr. Eric J. Daniels as Chief Development Officer, effective April 20, 2026. Dr. Daniels brings over 20 years of experience in biotechnology, having previously led development at Kiora Pharmaceuticals. His expertise is expected to accelerate the advancement of Plus Therapeutics' clinical pipeline, particularly in CNS oncology.
Read more →Plus Therapeutics has received Orphan Drug Designation from the FDA for REYOBIQ, aimed at treating pediatric malignant gliomas, which are aggressive brain tumors. This designation is significant as it extends to pediatric ependymoma, suggesting broader treatment applicability. The company emphasizes REYOBIQ's capability to deliver high-dose radiation directly to tumor sites, potentially enhancing patient outcomes in this underserved population. Furthermore, this designation provides several benefits, including seven years of market exclusivity upon approval.
Read more →Plus Therapeutics announced that the American Medical Association has approved a Proprietary Laboratory Analyses Current Procedural Terminology code for its CNSide CSF Tumor Cell Enumeration test, effective July 1, 2026. This dedicated billing code will assist in standardizing reimbursement processes and enhancing clinical adoption among physicians regarding CNS metastases. The company believes this milestone will support its U.S. commercial launch of CNS diagnostics and improve revenue growth. This achievement is expected to ease the complexities associated with reimbursement for healthcare providers.
Read more →The article discusses the emerging role of radiotherapeutics and isotopes in cancer treatment. It highlights how these advancements are changing therapeutic approaches and improving patient outcomes. The focus is on the potential benefits of isotopes in targeting cancer cells more effectively. However, the article does not provide specific details or case studies.
Read more →Plus Therapeutics has secured a coverage agreement with Highmark for its CNSide CSF assay, increasing the total covered lives to 75 million. This agreement is expected to enhance patient access and accelerate the adoption of CNSide in oncology centers. The assay has shown superior clinical utility and cost-effectiveness in managing leptomeningeal metastases.
Read more →Plus Therapeutics, Inc. has announced a 1-for-25 reverse stock split to comply with Nasdaq's minimum bid price requirement. This decision aims to increase the trading price of its common stocks, which will reduce the number of outstanding shares from approximately 171.5 million to around 6.86 million. The reverse stock split will take effect on April 2, 2026, and is intended to enhance shareholder value by improving market perceptions. However, the success of this strategy depends on the Company's ability to regain compliance with Nasdaq's listing standards.
Read more →Plus Therapeutics, Inc. announced the granting of inducement awards to two new employees under its 2015 New Employee Incentive Plan. The awards include options to purchase 300,000 shares and 300,000 restricted stock units (RSUs). The options have a 10-year term with a fair market value exercise price, while the RSUs vest over three years.
Read more →Plus Therapeutics, Inc. announced a reverse stock split of its common stock at a ratio of 1-for-25, effective April 2, 2026. This measure aims to increase the per share trading price to meet Nasdaq's minimum bid price requirement. Post-split, the outstanding shares will decrease from approximately 171.6 million to about 6.9 million. The company assures that this split does not alter stockholders' percentage interests, but it comes with risks related to compliance with listing requirements.
Read more →Plus Therapeutics has appointed Ron Andrews, a veteran in the diagnostics industry, to its Board of Directors. His extensive experience and connections are expected to positively impact the company's strategy, particularly in scaling its CNSide diagnostics technology. CNSide aims to improve the management of central nervous system cancers by utilizing cerebrospinal fluid analysis.
Read more →Plus Therapeutics is set to present a new analysis at the ISPOR 2026 Annual Meeting, highlighting the economic advantages of its CNSide assay for detecting leptomeningeal metastases. The study suggests that earlier detection and management using CNSide could lower healthcare costs by about 40%, emphasizing improved treatment timing and reduced hospitalization needs. This cost-of-care analysis supports the breakthrough potential of CNSide in clinical practice and its value to payers and health systems. The findings are expected to resonate with healthcare decision-makers at the conference in Philadelphia next May.
Read more →The article discusses a podcast episode featuring Dr. Marc Hedrick from Plus Therapeutics, focusing on the use of radiotherapeutics for treating central nervous system (CNS) cancers. The podcast aims to explore advancements in this area and the potential impact on patient care. It highlights the importance of innovative therapies in oncology.
Read more →Plus Therapeutics reported its financial results for Q4 2025 and outlined its strategic goals for 2026, focusing on the commercial rollout of CNSide and the pivotal trial readiness for REYOBIQ. The company anticipates increased expenditures in R&D and operations as it aims to enhance its product offerings and achieve breakeven for CNSide Diagnostics by 2027. REYOBIQ is positioned as a promising treatment for CNS tumors.
Read more →Plus Therapeutics announced the approval of a new Category III CPT code by the AMA for convection-enhanced delivery (CED) of REYOBIQ, aimed at treating recurrent glioblastoma and pediatric brain cancer. This milestone is expected to facilitate market access and reimbursement for the innovative treatment. The company is on track to complete enrollment in its Phase 2 trial in 2026 and initiate a Phase 1 trial for pediatric brain cancer.
Read more →The article discusses the growing recognition of theranostics as a pivotal future direction in the field of radiopharmaceuticals. This innovative approach aims to improve precision in cancer treatments, attracting significant investment and research interest. The potential benefits of theranostics could lead to advancements in personalized medicine for patients.
Read more →The article discusses the use of cookies on a website to enhance user experience. It outlines different categories of cookies, including necessary, functional, performance, analytics, and advertisement cookies. The content emphasizes the importance of user consent for cookie usage and how opting out may affect browsing experience.
Read more →The article discusses the integration of AI-powered diagnostics and targeted radiotherapy for central nervous system (CNS) cancers, featuring insights from Dr. Marc Hedrick of Plus Therapeutics. It highlights the potential advancements in treatment methodologies but lacks specific details on outcomes or developments.
Read more →Plus Therapeutics, Inc. has provided a business update focusing on its REYOBIQ clinical program and CNSide commercialization efforts. The company aims to enhance its operations in 2026 with the support of a recently completed $15 million funding round. Key milestones include advancing REYOBIQ's pivotal trial readiness and scaling up CNSide diagnostics.
Read more →Plus Therapeutics, Inc. will provide a business update and host a conference call on January 22, 2026, at 9:00 a.m. ET. The company focuses on developing precision diagnostics and radiopharmaceuticals for CNS cancers. The call will discuss additional details about their ongoing projects and future plans.
Read more →Plus Therapeutics (PSTV) is focusing on advancing its cancer treatments, particularly the radiotherapeutic REYOBIQ and the CNSide diagnostic platform. The company is preparing for the U.S. commercial relaunch of CNSide in Q3 2025, which addresses a large market for CNS metastases. Additionally, upcoming clinical trials indicate potential improvements in treatment outcomes, though challenges remain regarding liquidity and trial results. Overall, the company's innovative approaches could increase the chances of better survival rates for CNS cancer patients.
Read more →The article discusses the use of cookies on a website, detailing various categories of cookies such as necessary, functional, performance, and analytics cookies. It explains how these cookies enhance user experience and the importance of user consent for their usage. However, it does not provide specific insights or outlooks related to JPM 2026.
Read more →Plus Therapeutics, Inc. has announced the pricing of its upsized public offering, consisting of 39,473,684 units priced at $0.38 each, aiming to raise approximately $15 million. The offering will close on January 15, 2026, pending customary conditions. Proceeds will be utilized for working capital and general corporate purposes.
Read more →Plus Therapeutics has concluded a Type B meeting with the FDA regarding its REYOBIQ pivotal trial strategy for leptomeningeal metastases (LM). The discussion was constructive, leading to FDA recommendations for endpoints, including overall survival and patient-reported outcomes. The agency indicated that accelerated approval for REYOBIQ may be appropriate but highlighted that more data would be needed to support certain clinical endpoints. Plus Therapeutics plans to incorporate this feedback into its ongoing dose optimization trial and is preparing for a pivotal trial in the future.
Read more →The Phase 1 trial of RNL-186 has demonstrated promising results in patients with leptomeningeal metastases. Andrew Brenner, MD, PhD, emphasized the potential efficacy of the treatment, suggesting it could offer new hope for patients facing this challenging condition. The findings are significant as they pave the way for further research and development.
Read more →Plus Therapeutics' subsidiary, CNSide Diagnostics, has received lab licenses to provide its CNSide CSF Tumor Cell Enumeration test in California, Rhode Island, and Maryland. This expansion allows CNSide Diagnostics to offer its services in 48 states, supporting rapid diagnosis and treatment monitoring for CNS cancers. The CNSide platform has demonstrated high sensitivity and specificity, significantly impacting treatment decisions.
Read more →Plus Therapeutics has announced the expansion of its CNSide team, welcoming two new hires to enhance its diagnostic capabilities. The additions are part of the company's effort to improve laboratory operations while targeting a lucrative market for cerebrospinal fluid assays in CNS cancers. The new team members possess significant experience in diagnostics and regulatory affairs, which may facilitate the company's growth and product delivery. The company also issued stock options and RSUs as inducement grants to align the interests of these new hires with shareholders.
Read more →The article primarily discusses cookie consent and privacy policies related to website usage. It does not contain any pertinent information about PSTV or its activities in the biopharma sector. As such, it lacks relevance to stakeholders interested in PSTV's developments.
Read more →Plus Therapeutics, Inc. presented three positive clinical data updates for REYOBIQ at the WFNOS/SNO Annual Meeting in Honolulu. The trials highlighted the promising safety and efficacy in treating recurrent glioblastoma and leptomeningeal metastases, supporting further investigations and Phase 2 enrollment. Notably, the REYOBIQ trials showed no dosage limiting toxicity, with an overall survival benefit in glioblastoma patients. The company continues to advance its diagnostic portfolio alongside its therapeutic efforts.
Read more →The article discusses the use of cookies on a website, detailing the types of cookies utilized and their purposes. It emphasizes the importance of user consent for cookie storage and usage. The article also mentions the impact of opting out of certain cookies on the browsing experience.
Read more →The article discusses an interview with the CEO of Plus Therapeutics featured on Stocktwits. It provides insights into the company's strategies and future plans but lacks specific details about recent developments or product updates. The focus is primarily on the corporate narrative rather than specific financial or clinical data.
Read more →Plus Therapeutics is focused on advancing targeted radiotherapeutics aimed at treating rare and difficult-to-treat cancers. The company is exploring innovative therapies that leverage radiotherapeutic technology to improve patient outcomes. Their approach may provide new hope for patients facing challenging cancer diagnoses.
Read more →Plus Therapeutics will present results from its ReSPECT Phase 1 dose escalation study for leptomeningeal metastases at the 2025 San Antonio Breast Cancer Symposium. The study evaluates REYOBIQ, a novel injectable radiotherapy aimed at improving treatment outcomes for CNS cancers. The company has received significant funding for its clinical trials, emphasizing the importance of developing effective therapies for this severe condition.
Read more →The article discusses the Game on Glio podcast featuring Dr. Toral Patel and Dr. Andrew Brenner. The podcast aims to address critical topics related to glioblastoma and provide insights from experts in the field. It emphasizes the importance of sharing knowledge and experiences to improve patient outcomes.
Read more →Plus Therapeutics (PSTV) has completed a Type B meeting with the FDA regarding the clinical development of REYOBIQ for leptomeningeal metastases. The meeting was described as constructive, following multiple positive interactions with the FDA. The company plans to implement amendments to their trial in line with FDA recommendations, aiming to enhance the clinical development timeline. Further updates and guidance on next steps are expected in early 2026.
Read more →Plus Therapeutics has secured a national coverage agreement with Humana for its CNSide® Cerebrospinal Fluid Assay, effective October 29, 2025. This agreement extends coverage to approximately 16 million people, increasing total coverage to 67 million. The CNSide test has demonstrated superior clinical utility and has influenced treatment decisions in a significant majority of cases.
Read more →The article discusses a metastatic cancer assay aimed at providing answers for patients. It highlights the importance of understanding the assay's functionality and its potential impact on treatment decisions. However, specific details about the assay's effectiveness or clinical applications are not provided.
Read more →Plus Therapeutics, Inc. has been granted a 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement. This extension allows the company until May 11, 2026, to meet the criteria without an immediate need for a reverse stock split. The company is focused on developing targeted radiotherapeutics for CNS cancers, but must still navigate potential compliance challenges.
Read more →Plus Therapeutics is set to present results from its ReSPECT-LM clinical trial at the 40th SITC Annual Meeting. The trial data indicates that REYOBIQ is well-tolerated at higher doses, addressing a significant unmet need in treating leptomeningeal metastases. The drug has received FDA Fast Track and Orphan Drug Designation, with ongoing trials to optimize dosing.
Read more →The article discusses the potential of radiotherapeutics and early detection methods in addressing rare central nervous system (CNS) cancers. It highlights the challenges faced in diagnosing and treating these cancers and explores innovative approaches that may lead to breakthroughs in patient outcomes. The focus is on the intersection of technology and medicine in improving care for these patients.
Read more →The article discusses the Pharmaphorum podcast episode focused on targeted radiotherapeutics. It provides insights into the use of radiotherapeutics in cancer treatment, highlighting advancements and expert opinions. However, the article lacks specific details about the podcast content or key takeaways.
Read more →Plus Therapeutics reported its third quarter financial results, highlighting the successful introduction of the CNSide CSF diagnostics platform and positive Phase 1 trial results for REYOBIQ. The company aims to expand its commercial team and clarify its clinical development plan with the FDA. Additionally, it is focused on strengthening its financial position through strategic partnerships.
Read more →Plus Therapeutics has made significant strides in launching its CNSide Diagnostic platform, enhancing its operational capabilities and expanding its manufacturing footprint. The company appointed new leaders to strengthen its commercial strategy, aiming to address the unmet medical needs in CNS cancer diagnostics. A recent agreement with UnitedHealthcare further broadens access to their diagnostic services.
Read more →The article discusses the LiveLung webinar focused on leptomeningeal metastases. It outlines the importance of cookies for website functionality and user experience. The content emphasizes user consent for cookie usage and the various categories of cookies used on the site. However, it does not provide specific details about the webinar itself.
Read more →The article discusses the use of cookies on the BioHouston website, detailing the types of cookies used, their purposes, and user consent options. It emphasizes the importance of necessary cookies for website functionality and provides information about performance and analytics cookies. However, no specific news or updates regarding CNSide® or PSTV are mentioned.
Read more →The article discusses CNSide Diagnostics and its role in improving the diagnosis of leptomeningeal metastases. It highlights the importance of accurate diagnosis in managing this condition, although specific details about the technology or methods used by CNSide Diagnostics are not provided. The article does not present any clear positive or negative aspects of the development.
Read more →The article discusses the advancements in the radiopharmaceutical pipeline of PSTV, highlighting the anticipation surrounding upcoming key data. It emphasizes the importance of these developments in the context of the company's growth and strategic direction. However, specific details about the pipeline or data were not provided in the text.
Read more →Plus Therapeutics has achieved a notable milestone by obtaining insurance coverage for the first assay targeting metastatic central nervous system (CNS) cancer. This development is expected to improve patient access to essential diagnostic tools, potentially leading to better treatment outcomes. The company aims to leverage this coverage to enhance its market presence in the oncology sector.
Read more →Plus Therapeutics has secured a national coverage agreement with UnitedHealthcare for its CNSide® Cerebrospinal Fluid Assay, effective September 15, 2025. This agreement will provide coverage for over 51 million individuals in the U.S. The CNSide® assay is designed to improve diagnosis and treatment monitoring for patients with leptomeningeal metastases, demonstrating high sensitivity and specificity in clinical settings.
Read more →A Houston-based cancer diagnostics company has announced the initiation of patient testing as part of its new phase of development. This marks a significant step in their efforts to enhance cancer diagnostic capabilities. The company aims to improve patient outcomes through innovative testing methods.
Read more →Plus Therapeutics has announced an additional $1.9 million advance payment from CPRIT, part of a larger $17.6 million grant for its leptomeningeal cancer treatment program. This funding will support the development of REYOBIQ and the CNSide diagnostic test. The company is also pursuing further grant opportunities to strengthen its financial position.
Read more →CNSide Diagnostics has received CLIA accreditation for its cerebrospinal fluid (CSF) assay platform, which is expected to enhance the platform's credibility and marketability. This accreditation allows the company to offer its diagnostic services in a clinical setting, potentially increasing adoption rates. The move positions CNSide Diagnostics competitively within the diagnostics industry.
Read more →Plus Therapeutics has announced that its subsidiary, CNSide Diagnostics, has received accreditation from CMS for its clinical laboratory in Houston. This certification complies with CLIA regulations, marking a significant step towards the market release of the CNSide CSF Assay Platform. The accreditation underscores the company's commitment to quality and supports its strategy for U.S. market access.
Read more →Plus Therapeutics will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. CEO Marc H. Hedrick will engage in a fireside chat with H.C. Wainwright's Sean Lee, available on demand for registered investors. The company focuses on developing targeted radiotherapeutics for CNS cancers.
Read more →The article discusses the use of targeted radiotherapies for treating challenging central nervous system (CNS) cancers. It highlights the importance of innovative treatment approaches in addressing these complex conditions. However, specific details regarding the therapies or their effectiveness are not provided.
Read more →The article discusses the impact of precision medicine on cancer treatment and how developers are adapting to this evolving field. It highlights the importance of personalized approaches in improving patient outcomes. However, the article lacks specific examples or detailed insights into current developments or challenges faced by developers in this area.
Read more →The article features an interview with the President of CNSide®, discussing the company's initiatives and innovations in the medical device sector. It highlights the importance of their technology and its potential impact on patient care. However, specific details about the interview content are not provided in the text.
Read more →Plus Therapeutics has announced its compliance with Nasdaq Listing Rule 5550, confirming it meets both the Market Value of Listing Securities and the stockholders' equity requirements. The company has been granted an extension to comply with the bid price rule until November 12, 2025. However, it remains under a one-year monitoring period for the equity standard, which poses a risk of delisting if compliance is not maintained.
Read more →Plus Therapeutics announced positive results from the ReSPECT-LM Phase 1 trial of REYOBIQ for leptomeningeal metastases. The trial demonstrated a clinical benefit rate exceeding 75% and a manageable safety profile with no dose limiting toxicities. The findings suggest the treatment is feasible and effective, paving the way for further optimization and potential approval trials.
Read more →The article discusses the KOL Symposium at the SNO/ASCO CNS Metastases 2025 event. It primarily focuses on the use of cookies on the website, detailing the types of cookies and their purposes. There is no specific information about the symposium itself or any related biopharma news.
Read more →Plus Therapeutics has reported stockholders' equity exceeding $3 million, thereby complying with Nasdaq's Equity Rule. This follows a previous notification of non-compliance, which led to a hearing and a request for an extension. The company is now awaiting Nasdaq's confirmation of compliance.
Read more →Plus Therapeutics, Inc. reported its Q2 2025 financial results, highlighting advancements in its clinical and diagnostic initiatives. The company initiated the REYOBIQ dose optimization trial for patients with leptomeningeal metastases and launched the CNSide CSF assay platform in Texas. Financially, Plus Therapeutics experienced a net income of $5.2 million, influenced by a change in the fair value of derivative instruments. The company also received an advance payment of $1.6 million as part of a larger grant from CPRIT.
Read more →PSTV has filed an unaudited pro forma balance sheet to comply with Nasdaq's requirement of maintaining a minimum stockholders' equity of $2.5 million for continued listing. However, the independent accounting firm has not provided an audit or assurance on the pro forma numbers, raising concerns about potential adjustments. The reported stockholders' equity stands at approximately $3.19 million. This filing indicates the company's efforts to adhere to regulatory standards while also highlighting the uncertainty regarding its financial status.
Read more →Plus Therapeutics Inc. presented positive data from its CNSide CSF Assay Platform at the 2025 SNO/ASCO CNS Metastases Conference. The study analyzed 613 assays and showed a high detection rate of CSF tumor cells in 67% of patients with leptomeningeal metastases. The CNside has potential to influence treatment decisions and personalize therapy based on real-time shifts in tumor biology. This innovative platform could enhance clinical outcomes for patients suffering from central nervous system cancers.
Read more →The article discusses the ReSPECT-GBM study being conducted at the Mays Cancer Center. It highlights the use of innovative approaches in treating glioblastoma, a challenging type of brain cancer. However, the article lacks specific details about the study's outcomes or implications.
Read more →The article discusses the evolution of diagnostics and treatment for central nervous system cancer metastases. It highlights advancements in understanding the disease and the impact of new technologies on patient outcomes. However, specific details regarding recent developments or studies are not provided.
Read more →Plus Therapeutics, Inc. announced that its subsidiary, CNSide Diagnostics, will launch its CNSide cerebrospinal fluid testing services in Texas starting August 2025. With a focus on National Cancer Institute (NCI) Designated Cancer Centers, the CNSide assay is designed to better diagnose and manage patients at risk for leptomeningeal metastases. The assay has shown significant clinical advantages over current standards, having supported effective treatment decisions in the majority of cases. Over the next year, the company aims to broaden the regional availability of the CNSide platform.
Read more →The article discusses the importance of cookies on a website, emphasizing their role in ensuring basic functionalities and improving user experience. It details the different categories of cookies, such as necessary, functional, performance, and analytics cookies. The text also highlights user consent and the option to opt-out of certain cookies.
Read more →The article discusses the use of precision radiotherapeutics for targeting central nervous system (CNS) cancers. It highlights the potential benefits of this approach in improving treatment outcomes. However, specific details on clinical trials or results are not provided, leaving the discussion at a conceptual level.
Read more →Plus Therapeutics, Inc. has announced an advance payment of $1.6 million from the Cancer Prevention and Research Institute of Texas (CPRIT) as part of a larger $17.6 million grant. This funding is intended to accelerate the clinical development of their radiotherapeutic product, REYOBIQ, aimed at treating central nervous system cancers. Additionally, the company anticipates receiving around $6 million in further funding over the next 12 months. This financial support is viewed as a commitment to improving treatment options for rare but severe complications in cancer patients, such as leptomeningeal metastases.
Read more →Plus Therapeutics, Inc. announced the presentation of final clinical trial results for its radiotherapy REYOBIQ at the 2025 SNO/ASCO CNS Metastases Conference. The presentation, led by chief development officer Michael Rosol, emphasizes the promising safety profile and response signals from the ReSPECT-LM trial. Additionally, an educational symposium will delve into novel approaches to managing leptomeningeal metastases, featuring insights from leading experts in the field. The REYOBIQ is specifically designed to improve treatment outcomes for CNS cancer patients.
Read more →Plus Therapeutics announced the presentation of its CNSide CSF Assay Platform at the upcoming SNO/ASCO CNS Metastases Conference, scheduled for August 14-16, 2025, in Baltimore, MD. The presentations will focus on the clinical implications of the assay in managing central nervous system metastases, particularly in breast and non-small cell lung cancer patients with leptomeningeal disease. The data emphasizes the assay's ability to quantify tumor cells and provide actionable insights, representing a significant advancement in the field of cancer diagnostics.
Read more →Plus Therapeutics has initiated the treatment of initial patients in the ReSPECT-LM dose optimization trial for its radiotherapeutic REYOBIQ, aimed at managing leptomeningeal metastases. This trial follows promising Phase 1 study results and seeks to establish optimal dosing regimens to ensure safety and effectiveness. The company anticipates rapid enrollment aligned with FDA guidelines and is preparing to present further trial data at an upcoming conference. Backed by a $17.6 million grant from CPRIT, the trial aims to address a significant need for effective treatment options in a patient population with limited therapeutic alternatives.
Read more →Plus Therapeutics has announced the initiation of the ReSPECT-LM dose optimization trial for REYOBIQTM aimed at treating leptomeningeal metastases. This trial is designed to determine the optimal dosing schedule following encouraging results from earlier single-dose studies. The company has received a significant $17.6M grant from the Cancer Prevention & Research Institute of Texas to support the trial. The study will evaluate safety, tolerability, and efficacy in cancer patients across two Texas cancer centers initially, with potential site expansions in the future.
Read more →Plus Therapeutics announced a business update on its subsidiary, CNSide Diagnostics, which is set to launch a novel diagnostic platform aimed at central nervous system (CNS) cancers in the second half of 2025. The CNSide CSF Assay platform targets an underserved market estimated at over $6 billion, showcasing superior sensitivity and specificity compared to current standards. The company has established infrastructure for commercial operations and expects strong demand post-launch due to prior market familiarity and negotiated reimbursement agreements. Financial projections indicate CNSide will significantly contribute to Plus Therapeutics' operations starting fiscal year 2026.
Read more →Plus Therapeutics, Inc. has received FDA clearance for its Investigational New Drug application for REYOBIQ, aimed at treating pediatric patients with high-grade glioma and ependymoma. The trial, known as ReSPECT-PBC, is funded by a $3 million grant from the U.S. Department of Defense and will assess the safety and efficacy of the novel radiotherapeutic. This trial marks a significant advancement in the treatment options available for difficult-to-treat childhood brain tumors, which have traditionally seen poor outcomes. The company has seen promising results in adult trials, providing hope for this new therapy in a pediatric context.
Read more →Plus Therapeutics, Inc. has announced a business update scheduled for June 26, 2025, before market opening. The management team will follow up with a conference call at 9:00 a.m. ET to discuss further details. The company focuses on developing targeted radiotherapeutics for central nervous system cancers, with promising programs in leptomeningeal metastases and recurrent glioblastoma.
Read more →Plus Therapeutics has announced a comprehensive restructuring of its $15 million equity financing from March 2025. This restructuring effectively eliminates the potential issuance of up to 1.5 billion shares of common stock, thus reducing shareholder dilution. Key highlights include the cancellation of associated warrants and the implementation of provisions ensuring that future capital raised will prioritize repayment to current shareholders. The company has also withdrawn the related resale registration statement with the SEC, indicating significant changes in its financing strategy.
Read more →The article features an interview with Andrew Brenner, MD, PhD, discussing his insights and experiences in the field of cancer treatment. It highlights his perspectives on current trends and advancements in oncology. The content primarily focuses on his professional journey and contributions to cancer research.
Read more →The article features an interview with the CEO of Plus Therapeutics, discussing the company's strategic direction and recent developments. However, the content primarily focuses on website cookie policies rather than specific insights into the company or its operations. This lack of detailed information limits the overall impact of the interview.
Read more →The article features an interview with Andrew Brenner, MD, PhD, discussing various topics related to the biopharma industry. However, the content primarily focuses on website cookie policies rather than specific insights from the interview. This lack of detailed information may limit the article's relevance to readers seeking in-depth analysis.
Read more →Rhenium Obisbemeda has demonstrated improved survival rates in patients with recurrent glioblastoma. This treatment could provide a significant advancement in the management of this aggressive brain cancer. The findings suggest that Rhenium Obisbemeda may offer new hope for patients facing limited options.
Read more →Plus Therapeutics, Inc. recently announced its financial results for Q1 2025 and highlighted significant progress in its clinical programs. The company raised $15 million through private placement and received additional grant support, enhancing its cash position. Key developments include interim data for the REYOBIQ clinical trials demonstrating safety and efficacy, as well as organizational moves to strengthen its management team. However, the company reported a net loss of $17.4 million, which is an increase from the previous year, mainly due to rising legal costs.
Read more →Plus Therapeutics, Inc. has received a notification of deficiency from Nasdaq due to a delayed filing of its Quarterly Report on Form 10-Q for the period ended March 31, 2025. While this notification states that the company is not in compliance with Nasdaq Listing Rule 5250(c)(1), it does not impact the current listing of the company's securities. Plus Therapeutics has until July 21, 2025, to submit a plan to regain compliance, and the company is actively working to address this issue and resume its normal filing schedule.
Read more →Plus Therapeutics presented new data on its lead drug REYOBIQ at the Nuclear Medicine and Neurooncology Conference. The data highlighted safety and clinical efficacy, with a 76% clinical benefit rate among patients with leptomeningeal metastases. The study demonstrated that multiple doses could lead to long-term survival, with significant immune responses noted. However, there were instances of grade 4 toxicity, and the terminal nature of leptomeningeal metastases remains a pressing challenge.
Read more →Plus Therapeutics, Inc. (PSTV) announced its participation in the D. Boral Capital Inaugural Global Conference scheduled for May 14, 2025, at The Plaza Hotel in New York City. The company's CEO, Marc H. Hedrick, will hold one-on-one meetings with attendees to discuss its innovative radiotherapeutic programs targeting CNS cancers. Plus Therapeutics is focused on enhancing clinical outcomes through its advanced platform technologies. The company also plans to commercialize its CNSide™ diagnostic platform in the U.S. in 2025.
Read more →The article discusses a new potential treatment for brain cancer proposed by Andrew Brenner, MD, PhD. It explores innovative approaches in the field, although specific details about the treatment or its efficacy are not provided. The article emphasizes the need for further research and clinical trials to validate these new methods.
Read more →Plus Therapeutics, Inc. has appointed Kyle Guse to its Board of Directors, where he will serve as chair of the Audit Committee and on the Compensation Committee. Guse, a seasoned executive with over 30 years of experience in finance and law, is expected to significantly impact the company's strategic direction. Plus Therapeutics is developing targeted radiotherapeutics for CNS cancers and aims to enhance clinical outcomes with its innovative pipeline. Guse expressed optimism about the company's potential in the market and his commitment to maximizing value for stakeholders.
Read more →The article discusses the latest developments in targeted radiotherapeutics as explained by Plus Therapeutics CEO Dr. Marc Hedrick. It highlights the company's focus on innovative treatments and their potential impact on cancer therapy. However, specific details regarding new products or clinical trials are not provided.
Read more →Plus Therapeutics has presented new data on REYOBIQ in the ReSPECT-LM clinical trial, showing promising results for patients with leptomeningeal metastases. In a Phase 1 trial, REYOBIQ demonstrated a 75% clinical benefit rate, with no dose limiting toxicity observed in initial cohorts. The treatment effectively delivered high doses of radiation to affected areas, indicating its potential utility in managing this severe condition. Further detailed data will be available following the upcoming Nuclear Medicine and Neurooncology conference.
Read more →Plus Therapeutics reported its financial results for Q4 and the full year of 2024, highlighting significant advancements including a $15 million financing that accelerates the development of REYOBIQ and the upcoming launch of the CNSide diagnostic platform. The firm has garnered positive safety and efficacy results for REYOBIQ in treating CNS cancers. They also experienced an increase in operating loss, coinciding with a decrease in cash reserves. The company expects 2025 to be a pivotal year as they aim to become a revenue-generating entity with the commercial launch of CNSide.
Read more →The article appears to be a privacy notice regarding cookie usage on a website, rather than providing any substantive content related to the Nano Cap Podcast or the company PSTV. It outlines the types of cookies used and their purposes but lacks any details about the podcast itself or its relevance to PSTV.
Read more →Plus Therapeutics has announced that the FDA has conditionally accepted the proprietary name REYOBIQ™ for its lead drug candidate rhenium Re186 obisbemeda. This marking a step towards commercialization and aims to foster stakeholder engagement. REYOBIQ™ is currently under investigation for treating recurrent glioblastoma and leptomeningeal metastases. The drug is intended to provide targeted radiation therapy, potentially improving clinical outcomes for patients.
Read more →Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, announced it will report its fourth quarter and full year 2024 financial results on March 27, 2025. The company will also host a conference call and webcast at 5:00 p.m. ET to discuss these results and provide an update on corporate affairs. Plus Therapeutics focuses on developing targeted radiotherapeutics for central nervous system cancers, employing advanced platform technologies to improve clinical outcomes.
Read more →Plus Therapeutics, Inc. announced that it has regained compliance with Nasdaq's minimum stockholders' equity requirement, ensuring its common stock continues to be listed and traded on The Nasdaq Capital Market. This development comes as the company advances its innovative pipeline of targeted radiotherapeutics aimed at treating central nervous system cancers. Plus Therapeutics specializes in using image-guided local beta radiation and targeted drug delivery approaches to enhance clinical outcomes for challenging cancer cases, such as leptomeningeal metastases and recurrent glioblastoma.
Read more →The article discusses the use of cookies on a website, detailing the types of cookies used and their purposes. It explains necessary cookies for basic functionalities, as well as functional, performance, analytics, advertisement, and other uncategorized cookies. The text emphasizes user consent and the option to opt-out of certain cookies.
Read more →Plus Therapeutics has announced the peer-reviewed publication of Phase 1 trial results for Rhenium (186Re) Obisbemeda in Nature Communications, demonstrating significant potential in treating recurrent glioblastoma. The study found that patients receiving higher doses had a median overall survival of 17 months, which is more than double the standard treatment. The drug showed a favorable safety profile, with no dose-limiting toxicity reported. The company is now progressing to a Phase 2 trial, ReSPECT-GBM, which is currently enrolling patients.
Read more →Plus Therapeutics has received Orphan Drug Designation from the U.S. FDA for Rhenium (186Re) Obisbemeda, which aims to treat leptomeningeal metastases in lung cancer patients. This designation is a critical milestone as it provides several advantages, including potential market exclusivity and tax credits for clinical trials. The company is progressing into further clinical trials following the initial Phase 1 testing, positioning itself to meet an urgent medical need in a patient population with limited treatment options.
Read more →Plus Therapeutics, Inc. has granted stock options to Dr. Michael Rosol, its new Chief Development Officer, to encourage his employment. The options total 30,000 shares and will vest over four years, contingent on Dr. Rosol's ongoing service. This move aims to align the interests of Dr. Rosol with those of the company's shareholders. The grants were made outside of the company's standard incentive plan but follow similar conditions.
Read more →Plus Therapeutics announced a private placement to raise approximately $15 million in gross proceeds to advance its therapies for central nervous system cancers. The offering consists of common and pre-funded units, which will finance operations and repay certain outstanding promissory notes. The transaction is subject to customary closing conditions and Nasdaq confirmation to avoid delisting. The funds are critical for the company's strategic development and achieving key milestones.
Read more →Plus Therapeutics has successfully completed the ReSPECT-LM Phase 1 trial for its lead drug, Rhenium (186Re) Obisbemeda, aimed at treating leptomeningeal metastases. The trial established a recommended Phase 2 dose (RP2D) of 44.1 mCi without any observed dose-limiting toxicities. Notably, one patient achieved a complete response, suggesting the drug's potential efficacy. The company is now advancing to both a single dose-expansion Phase 2 trial and a multiple-dose Phase 1 trial, while engaging the FDA for future steps.
Read more →Plus Therapeutics has announced key leadership appointments for its subsidiary, CNSide Diagnostics, including Russell Bradley as President and General Manager. The new team aims to advance the commercialization of proprietary diagnostics for leptomeningeal disease, a rare cancer complication. The company is preparing for an upcoming market introduction in 2025, leveraging Bradley's extensive experience in diagnostics and life sciences. Additionally, Dr. Jonathan Stein has been appointed as the new Medical Director to enhance the scientific oversight of CNSide's developments.
Read more →Plus Therapeutics has appointed Dr. Michael Rosol as Chief Development Officer, tasked with leading the company’s clinical and biomarker development efforts. This appointment comes at a crucial time as Plus Therapeutics prepares to transition from mid-stage trials to pivotal trials in the upcoming year. Dr. Rosol has extensive experience in oncology and drug development, which is expected to benefit the company’s pipeline, particularly concerning severe CNS cancers. The company is developing targeted radiotherapeutics aimed at improving clinical outcomes for patients suffering from difficult-to-treat cancers.
Read more →Plus Therapeutics, Inc. has successfully closed a private placement financing for approximately $3.7 million, complemented by a $2.0 million advance from the Cancer Prevention and Research Institute of Texas (CPRIT). This funding will be used to support the clinical development of Rhenium (186Re) Obisbemeda for leptomeningeal metastases, alongside the company's CNSide diagnostic test. The capital raised is expected to bolster the company's position for future pivotal trials, particularly focusing on the increasing incidence of leptomeningeal metastases among cancer patients.
Read more →Plus Therapeutics presented promising interim data from its ReSPECT-LM Phase 1 clinical trial at the 2024 San Antonio Breast Cancer Symposium. The trial evaluated Rhenium (186Re) Obisbemeda in breast cancer patients with leptomeningeal metastases, reporting favorable responses in the majority of evaluable patients. Key highlights included an overall survival median of 9 months for patients and strong clinical benefit rates. The company plans to initiate a single-dose expansion cohort in Q1 2025 to further assess treatment efficacy.
Read more →The article discusses the SNO Annual LM Symposium, focusing on the use of cookies on the website. It explains the different categories of cookies, their purposes, and how users can manage their cookie preferences. However, it does not provide specific details about the symposium itself.
Read more →Plus Therapeutics, Inc. plans to present interim data from its Phase 1 trial of Rhenium (186Re) obisbemeda for treating leptomeningeal metastases at the 2024 San Antonio Breast Cancer Symposium. This novel injectable radiotherapy aims to deliver targeted radiation to CNS tumors effectively. Leptomeningeal metastases are a serious complication in breast cancer, with currently no FDA-approved therapies available. This presentation comes as part of ongoing efforts to address significant challenges in treatment for these patients.
Read more →Plus Therapeutics has renewed its Master Services Agreement with Telix IsoTherapeutics Group, securing a reliable supply chain for the radioisotope Re-186, crucial for its lead radiotherapeutic candidate, Rhenium (186Re) Obisbemeda. This agreement aims to enhance production capabilities and support upcoming clinical trials for the treatment of CNS tumors. The partnership positions Plus Therapeutics to effectively meet the demands of late-stage clinical trials and potential commercial needs with a comprehensive supply chain strategy.
Read more →Plus Therapeutics, Inc. presented positive interim data from its ReSPECT-LM Phase 1 clinical trial for Rhenium (186Re) Obisbemeda at the 2024 SNO Annual Conference. The study reported favorable response rates and median overall survival for patients with leptomeningeal metastases, achieving absorbed radiation doses significantly higher than existing treatments. The company received FDA agreement to advance into multiple-dose trials, reflecting a commitment to further enhance treatment options for this serious condition. The completion of the ongoing Cohort 6 and the launch of the Phase 1b expansion cohort trial are anticipated in the near term.
Read more →Plus Therapeutics, through its subsidiary CNSide Diagnostics, is set to present positive data from the FORESEE trial, highlighting the effectiveness of the CNSide CSF Assay in diagnosing leptomeningeal metastases (LM). The trial showed that the CNSide technology influenced clinical management for over 90% of cases and significantly improved diagnostic sensitivity compared to traditional methods. The assays demonstrated increased specificity and the ability to identify actionable mutations, thus enhancing treatment decision processes for affected patients. The findings will be presented at the Society for Neuro-Oncology Annual Meeting in Houston, Texas.
Read more →Plus Therapeutics, Inc. will present new data on the CNSide Cerebrospinal Fluid (CSF) Assay at the SNO Annual Meeting. The presentation reveals that the assay identified extensive mutational changes in patients with leptomeningeal metastases, highlighting its utility in treatment selection. Additionally, the data suggest that genetic profiles in these patients are dynamic, which may influence future treatment strategies, particularly the use of Rhenium (186Re) Obisbemeda. The CNSide platform is expected to become commercially available in 2025, marking a potential advancement in managing this complicated disease.
Read more →Plus Therapeutics reported its Q3 2024 financial results, highlighting significant advancements in their clinical trials. The FDA has granted the company approval to initiate a Phase 1 trial for Rhenium Obisbemeda in treating leptomeningeal metastases. Additionally, positive data from the ReSPECT-GBM trial was presented at a major conference, underscoring the treatment's safety and efficacy. However, the company also reported an increased operating loss and a decrease in cash reserves, reflecting ongoing financial challenges.
Read more →Plus Therapeutics, Inc. has announced a strategic Manufacturing Services Agreement with SpectronRx for the production of Rhenium (186Re) Obisbemeda, a radiotherapeutic for CNS cancers. This partnership is intended to enhance supply chain capabilities as Plus Therapeutics prepares for late-stage clinical trials set to begin in 2025. SpectronRx will utilize its advanced facilities to meet the demand for this innovative therapy, which aims to improve treatment outcomes for patients with recurrent glioblastoma and leptomeningeal metastases. The collaboration underscores both companies' commitment to advancing nuclear medicine and addressing critical patient needs in oncology.
Read more →Plus Therapeutics, Inc. announced plans to release its third quarter 2024 financial results on November 14, 2024, following market close. The company's management team will host a conference call at 5:00 PM ET to discuss the financial results and offer a corporate update. Plus Therapeutics focuses on developing targeted radiotherapeutics for challenging cancers of the central nervous system, aiming to enhance clinical outcomes for patients. The company is actively involved in clinical trials, particularly for recurrent glioblastoma and leptomeningeal metastases.
Read more →The article discusses a presentation by Dr. Andrew Brenner at the Glioblastoma Patient Summit. However, it lacks specific details about the content of the presentation or any outcomes related to glioblastoma treatment. The focus appears to be on the event logistics rather than substantive medical advancements or findings.
Read more →Plus Therapeutics, Inc. will present at the 2024 Society for Neuro-Oncology Annual Meeting, highlighting results from the ReSPECT-LM trial for its novel radiotherapy, Rhenium (186Re) obisbemeda, aimed at treating leptomeningeal metastases (LM). The company also plans to showcase findings from the FORESEE Trial, which focuses on diagnosis and monitoring of LM through circulating tumor cells. An educational symposium will be held to discuss recent developments in LM therapeutic and diagnostic programs. The condition presents significant challenges due to low survival rates and lack of effective treatments, which Plus aims to address with its innovations.
Read more →Plus Therapeutics provided an update on its ReSPECT-GBM Phase 1/2 clinical trial during the 2024 Congress of Neurological Surgeons, highlighting the potential of Rhenium (186Re) Obisbemeda in treating recurrent glioblastoma. The trial has enrolled 42 patients, demonstrating a favorable safety profile and promising efficacy, with 89% of patients exceeding a minimal radiation dose threshold. The expansion of the trial to new clinical sites is expected to enhance patient enrollment and expedite results in this challenging cancer landscape.
Read more →Plus Therapeutics will present new interim data from its ReSPECT-GBM Phase 2 clinical trial at the 2024 Congress of Neurological Surgeons Annual Meeting. The trial focuses on treating recurrent glioblastoma using the novel injectable radiotherapy, Rhenium (186Re) Obisbemeda, which aims to deliver targeted radiation to CNS tumors. With no FDA-approved treatments significantly extending life for GBM patients, this presentation is expected to shed light on a promising alternative therapy. The conference will be held from September 28 to October 2, 2024, in Houston, Texas.
Read more →Plus Therapeutics, Inc. will be presenting a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference, taking place from September 9-11, 2024. Company President Marc H. Hedrick, M.D. will discuss the company's advancements in developing targeted radiotherapeutics for central nervous system cancers. The presentation will be available on-demand, and the company also invites requests for one-on-one meetings during the event. This appearance highlights Plus Therapeutics' commitment to enhancing treatment options for difficult-to-treat cancers.
Read more →The article discusses the SNO/ASCO CNS Metastases LM Symposium, focusing on the use of cookies on the website. It outlines the types of cookies utilized, including necessary, functional, performance, and analytics cookies, and their purposes. The text emphasizes user consent and the importance of cookies for website functionality.
Read more →Plus Therapeutics, Inc. reported its financial results for Q2 2024 and highlighted recent achievements, including positive interim results for Rhenium (186Re) Obisbemeda in treating leptomeningeal metastases. The company noted a median overall survival of 12 months for patients in the ReSPECT-LM Phase 1 trial. Additionally, the CNSide diagnostic platform demonstrated significant clinical utility, meeting its primary endpoint. The firm also received a $3.3 million grant from CPRIT to facilitate continued development in this area.
Read more →Plus Therapeutics presented promising results from its CNSide platform at the 2024 SNO/ASCO CNS Metastases Conference, indicating enhanced clinical utility for diagnosing and managing leptomeningeal metastases (LM). The FORESEE trial revealed that CNSide influenced treatment decisions in over 90% of cases, with diagnostic sensitivity reaching 80%, compared to just 29% with traditional methods. These results highlight the potential of CNSide in providing earlier and more precise diagnoses, possibly improving therapeutic outcomes for patients suffering from LM.
Read more →Plus Therapeutics has presented promising interim results from its ongoing ReSPECT-LM Phase 1 clinical trial, demonstrating the safety and feasibility of administering Rhenium (186Re) Obisbemeda in patients with leptomeningeal metastases. The trial data showed a significant mean reduction in circulating tumor cells and a median overall survival of 12 months for participants. Furthermore, the trial has received FDA Fast Track and Orphan Drug designations, signaling potential regulatory support for this innovative treatment approach. No serious toxicities were reported, highlighting the therapy's favorable safety profile.
Read more →Plus Therapeutics, Inc. has announced that it will report its second quarter financial results on August 14, 2024, followed by a conference call to discuss the results and provide corporate updates. The call is scheduled to take place at 5:00 p.m. ET. The company focuses on developing targeted radiotherapeutics aimed at treating central nervous system cancers. Plus Therapeutics emphasizes its commitment to enhancing clinical outcomes through its innovative technologies.
Read more →Plus Therapeutics will present significant developments in their leptomeningeal metastases programs at the upcoming SNO/ASCO Conference in Denver. Key presentations will include updates on the safety and feasibility of Rhenium (186Re) obisbemeda, a targeted therapy for CNS tumors. The company aims to enhance clinical outcomes through its innovative approaches and engage influential figures in cancer research during the event. This showcases Plus Therapeutics' commitment to addressing this challenging and often terminal complication of cancer.
Read more →The article appears to be an interview with the Scott Hamilton CARES Foundation. However, the content primarily discusses website cookie policies rather than providing insights into the foundation or its activities. There is no substantial information regarding the foundation's initiatives or impact.
Read more →Plus Therapeutics, Inc. announced that Dr. Melissa Moore will present at the Gordon Research Conference on July 8, 2024, in Newry, Maine. The presentation will cover the clinical data from the ReSPECT-GBM and ReSPECT-LM studies, focusing on their lead radiotherapeutic, rhenium (186Re) obisbemeda, aimed at treating recurrent glioblastoma and leptomeningeal metastases. This event highlights the company's commitment to developing advanced therapies for challenging CNS cancers.
Read more →Plus Therapeutics has announced the appointment of Dr. Greg Fuller as Vice President of Medical Affairs and Medical Director, strengthening its leadership team. The company received a $3.3 million advance payment from the Cancer Prevention & Research Institute of Texas (CPRIT) to support the development of rhenium (Re186) obisbemeda and the CNSide diagnostic test. CNSide demonstrates high sensitivity for leptomeningeal metastases detection and is set to be commercially launched by Q4 2024. The funding aims to enhance clinical trials and support the commercialization of its products.
Read more →The article features an interview with Marc Hedrick, M.D., discussing glioblastoma research. It highlights the importance of ongoing studies and potential advancements in treatment options. The conversation emphasizes the challenges faced in glioblastoma research and the need for continued support and funding in this area.
Read more →The Musella Foundation is hosting a patient webinar focused on recurrent glioblastoma. This event aims to provide essential information and support for patients dealing with this aggressive form of brain cancer. Details regarding the date, time, and registration process for the webinar were not included in the article.
Read more →Plus Therapeutics has reported its financial results for the first quarter of 2024, highlighting a private placement opportunity of up to $19.25 million and the receipt of a $3 million grant from the Department of Defense to support its brain cancer treatment efforts. The company has made strides in clinical advancements, including the acquisition of a diagnostic portfolio. While the cash balance saw a decline, overall financial losses have reduced compared to the same period last year, indicating a potential stabilizing trajectory as they aim for future milestones.
Read more →Plus Therapeutics, Inc. announced it will report its financial results for the first quarter of 2024 on May 15, post-market close. The company will host a conference call that same day at 5:00 PM ET to discuss the results and provide a corporate update. As a clinical-stage pharmaceutical company, Plus Therapeutics focuses on developing targeted radiotherapeutics for central nervous system cancers, emphasizing innovation and strategic partnerships.
Read more →Plus Therapeutics has acquired the CNSide diagnostic platform aimed at improving the diagnostic accuracy of leptomeningeal metastases (LM), which are often underdiagnosed. The company's topline data from the FORESEE clinical trial showed success in meeting the primary endpoint of clinical utility for the CNSide test in patients with LM from breast or non-small cell lung cancer. This acquisition is expected to augment the market for their lead radiotherapeutic candidate, rhenium (Re186) obisbemeda, as the company plans to seek partnerships and advance its development efforts.
Read more →Plus Therapeutics, Inc. has announced the acquisition of the CNSide cerebrospinal fluid diagnostic portfolio, aiming to improve diagnosis and treatment for CNS cancers. The company will provide topline data from its FORESEE trial at the SNO/ASCO Meeting in August 2024. An investor call is planned for May 9, 2024, where company leadership will discuss the acquisition's rationale and key updates. The FORESEE trial specifically targets patients with leptomeningeal metastases, a challenging condition with limited current treatment options.
Read more →Plus Therapeutics, Inc. announced a securities purchase agreement to raise up to $18 million through a private placement with institutional investors and insiders. Initial funding will provide approximately $6.5 million, with the potential for an additional $11.5 million through the exercise of warrants. This financing aims to support the company’s Re-SPECT LM clinical development program. The private placement is expected to close by May 8, 2024, pending customary closing conditions. Plus Therapeutics specializes in developing targeted radiotherapeutics for CNS cancers.
Read more →Plus Therapeutics has been awarded $3 million by the U.S. Department of Defense to support its targeted radiotherapeutics pipeline, particularly for treating pediatric brain cancer. The funding is expected to commence in Q3 2024 and will aid in expanding the company's Phase 1 trial for Rhenium (186Re) obisbemeda, a novel injectable radiotherapy. This financial boost will enhance Plus Therapeutics' operations and clinical development efforts, extending its cash runway through late 2025.
Read more →Plus Therapeutics, Inc. announced its intention to present a poster at the National Comprehensive Cancer Network (NCCN) 2024 Annual Conference. The poster will focus on the Phase 1 Dose Escalation Trial of Rhenium (186Re) Obisbemeda in treating Leptomeningeal Metastases. This event will take place from April 5-7, 2024, in Orlando, Florida, and aims to share updates on the initial safety and feasibility of their therapy. The presentation will be led by the Chief Medical Officer, Norman LaFrance, MD.
Read more →Plus Therapeutics participated in the Benzinga Virtual Healthcare Summit, highlighting their ongoing commitment to advancing healthcare solutions. The event provided a platform for discussing innovations in the biopharma sector. However, specific details about their presentations or announcements were not included in the article.
Read more →Plus Therapeutics has announced the successful validation and implementation of its CSF-01 diagnostic test, aimed at identifying adenocarcinoma and melanoma cells in leptomeningeal cancer. The CSF-01 test will serve as an exploratory endpoint in the ReSPECT-LM trials, with promising early data demonstrating a 53% reduction in tumor cells. Further clinical utility results are expected to be shared in mid-2024, enhancing the potential for improved diagnostics in leptomeningeal metastases treatment. The company is also exploring partnerships to maximize the diagnostic use of CSF-01 in CNS cancers.
Read more →Plus Therapeutics has released a corporate presentation outlining forward-looking statements regarding its development of rhenium (Re) obisbemeda for treating central nervous system (CNS) cancers. The presentation details upcoming clinical trials such as ReSPECT-GBM, ReSPECT-LM, and ReSPECT-PBC, highlighting the potential benefits and expected outcomes. However, it also acknowledges various risks including the early stage of their product candidates, funding challenges, and market competition that may impact future performance. The company emphasizes the promising nature of its technology in overcoming traditional treatment limitations for CNS cancers.
Read more →The article discusses the JonesTrading Fireside Chat, which appears to focus on the use of cookies on a website. It outlines the types of cookies used, their purposes, and the importance of user consent for cookie storage. However, there is no specific information about the Fireside Chat itself or any related biopharma content.
Read more →Plus Therapeutics has completed dosing in Cohort 5 of the ReSPECT-LM Phase 1 clinical trial for rhenium (186Re) obisbemeda. Eighteen patients have been dosed without observing any dose limiting toxicities. The company plans to initiate dosing in Cohort 6 in Q2 2024, pending approval from the Data Safety Monitoring Board. The FDA has granted Fast Track and Orphan Drug designations for the treatment, and the initiative is supported by funding from the Cancer Prevention & Research Institute of Texas.
Read more →Plus Therapeutics reported its fourth quarter and full year 2023 financial results, showcasing advancements in their clinical trials. The company began enrollment for the fifth cohort in the ReSPECT-LM Phase 1 trial and plans to expand its ReSPECT-GBM Phase 2 trial. Management highlighted a sufficient cash runway to fund operations through 2025 and outlined key upcoming milestones, including presenting interim data and preparing for pivotal trials. However, the company's cash position has decreased significantly compared to the previous year.
Read more →Plus Therapeutics, Inc. has announced it will report its fourth quarter and full year 2023 financial results on March 5, 2024, after market close. Following the announcement, the company's management will conduct a conference call to discuss the results and provide a corporate update. The company is focused on developing targeted radiotherapeutics for central nervous system cancers, indicating ongoing commitment to research and innovation in treatment options.
Read more →Plus Therapeutics, Inc. has announced updates regarding its financial guidance for 2024, including the receipt of $3.3 million in grant revenue and a forecasted $6.9 million in additional grant revenue. The company has also entered into a debt restructuring agreement with Pershing Capital that will reduce its cash burn by $3.7 million. With these developments, Plus Therapeutics aims to strengthen its balance sheet and extend its operational runway until at least the second half of 2025. The funding supports the company's efforts in developing targeted radiotherapeutics for CNS cancers.
Read more →The article discusses a KOL event related to the ReSPECT-GBM study. However, it does not provide specific details about the event, its outcomes, or implications for the study. The content primarily focuses on cookie consent and website functionality, lacking substantive information on the ReSPECT-GBM initiative.
Read more →Plus Therapeutics has entered into a partnership with K2bio to advance the analysis of cerebrospinal fluid (CSF) tumor and molecular biomarkers for central nervous system (CNS) cancers. This collaboration aims to enhance both diagnostic and therapeutic strategies as part of Plus Therapeutics' ReSPECT-LM trial for rhenium (186Re) obisbemeda. Initial testing is scheduled for the first quarter of 2024, supported by grant funding from the Cancer Prevention & Research Institute of Texas. The company has reported promising results, including a significant reduction in CSF tumor cells from early trial cohorts, and has received Fast Track designation from the FDA.
Read more →Plus Therapeutics, Inc. announced that Dr. Marc H. Hedrick will present at the 5th Targeted Radiopharmaceuticals Summit Europe on December 6, 2023, in Berlin, Germany. The presentation will cover their innovative approach using Re-186 radiolabelled nanoliposomes for treating rare brain and spinal cord tumors. The company is working on targeted radiotherapeutics to improve outcomes for patients facing challenging cancers, particularly recurrent glioblastoma and leptomeningeal metastases. Despite the promising focus, the challenges faced during early development stages and clinical trials pose risks to future outcomes.
Read more →Plus Therapeutics has reported promising interim data from its ReSPECT-GBM Phase 2 trial at the Society for NeuroOncology Annual Meeting. The data shows a median overall survival of 13 months in patients with recurrent glioblastoma, notably surpassing the current standard of care by 63%. Additionally, the trial showcases a median progression-free survival of 11 months and a favorable safety profile for the lead radiotherapeutic, Rhenium (186Re) Obisbemeda. The company plans to host a Key Opinion Leader webinar to discuss these findings further.
Read more →Plus Therapeutics will host a virtual Key Opinion Leader (KOL) event on November 20, 2023, to discuss new Phase 2 data from the ReSPECT-GBM study presented at the Society for NeuroOncology Conference. The event will feature expert insights into Rhenium (186Re) obisbemeda's potential in treating recurrent glioblastoma and its impact on the current treatment landscape. Dr. Andrew Brenner and other neuro-oncology specialists will contribute to the discussions, followed by a live Q&A session. Plus Therapeutics aims to improve outcomes for patients with central nervous system cancers through targeted radiotherapeutics.
Read more →Plus Therapeutics has received Orphan Drug Designation from the FDA for its investigational drug, rhenium (186Re) obisbemeda, targeting breast cancer with leptomeningeal metastases. This designation acknowledges the urgent need for effective treatments for this rare condition, which currently lacks FDA-approved options. The company is advancing its ReSPECT-LM trial and recently completed enrollment in Cohort 4, with plans to move forward following safety reviews. The FDA had previously granted Fast Track designation, emphasizing the drug's promise in addressing unmet medical needs.
Read more →Plus Therapeutics, Inc. has announced a new share repurchase program authorized by its Board of Directors, allowing the company to buy back up to $500,000 of its common stock. This initiative is aimed at enhancing long-term value for shareholders and reflects the company's confidence in its strategic priorities and future. The share repurchases will be funded through available cash and may occur over the next year, subject to market conditions and lender consent. However, the company retains the option to discontinue or suspend the program at any time.
Read more →Plus Therapeutics reported its third-quarter financial results, highlighting new survival data from 15 patients in the Phase 2 ReSPECT-GBM trial, which will be presented at the upcoming SNO Annual Meeting. The company's current cash position is $11 million, bolstered by an expected grant of $10.2 million from CPRIT, enough to sustain operations into 2025. Additionally, dosing has been completed in Cohort 4 of the Phase 1 ReSPECT-LM trial for leptomeningeal metastases. A conference call will be held to discuss these results in further detail.
Read more →Plus Therapeutics, Inc. announced its participation in the Society for NeuroOncology's 28th Annual Meeting, set for November 15-19, 2023, in Vancouver, Canada. The company will present four posters and an oral presentation focused on the Phase 2 trial data of Rhenium-186 Obisbemeda for recurrent glioblastoma. Additionally, it will host a virtual key opinion leader webinar featuring Dr. Andrew Brenner to discuss the new data. This engagement underlines the company's commitment to advancing treatment options in the field of central nervous system cancers.
Read more →Plus Therapeutics, a clinical-stage pharmaceutical company, announced that it will reveal its financial results for the third quarter of 2023 on October 31. Subsequently, the management team will host a conference call at 5:00 PM ET to discuss these results and provide a corporate update. The company focuses on developing targeted radiotherapeutics for central nervous system cancers, aiming to improve patient outcomes. Investors can register for the call, and recordings will be available afterward.
Read more →Plus Therapeutics has announced the completion of dosing in Cohort 4 of its ReSPECT-LM Phase 1/2a clinical trial for the treatment of leptomeningeal metastases using rhenium (186Re) obisbemeda. This milestone follows promising results from earlier cohorts, which reported a 53% reduction in tumor cell counts. The company plans to begin dosing in Cohort 5 pending safety review, while key updates from the trial are expected at the upcoming Society for Neuro-Oncology Annual Meeting. Additionally, Plus Therapeutics has secured a grant to support the trial's continuation.
Read more →Plus Therapeutics, Inc. announced its participation in two important upcoming healthcare conferences: the Jones Trading 2023 Healthcare Summit and the ThinkEquity Conference. Management will engage in one-on-one investor meetings at both events, enhancing the company’s visibility in the biopharma sector. Plus Therapeutics focuses on developing advanced radiotherapeutics targeted at central nervous system cancers, aiming to improve patient outcomes through its innovative approaches.
Read more →The article discusses an interview conducted at the NYSE with IPO Edge. However, it does not provide specific details about the content of the interview or any significant developments related to PSTV. The focus appears to be on website cookie policies rather than the interview itself.
Read more →Plus Therapeutics, Inc. has announced the receipt of a $1.9 million advance payment from the Cancer Prevention & Research Institute of Texas (CPRIT) as part of a larger grant awarded in 2022. The funds will aid the progress of the ReSPECT-LM clinical trial, which focuses on the treatment of leptomeningeal metastases using rhenium (186Re) obisbemeda. Additionally, the Company plans to present data from this trial at the CPRIT Innovations in Cancer Prevention and Research Conference, scheduled for October 2-3, 2023, in Galveston, Texas.
Read more →Plus Therapeutics has entered into a licensing agreement with Biocept to obtain access to the CNSide assay, a diagnostic tool for cerebrospinal fluid analysis in CNS cancer patients. This is significant as the assay is considered the gold standard, particularly for patients undergoing CNS radiotherapy. The license aims to enhance the diagnostic capabilities for patients with leptomeningeal metastases, improving management of their condition. In exchange, Plus Therapeutics will provide common stock to Biocept and has the option for exclusivity in the future, highlighting its strategic focus in CNS cancer treatment.
Read more →Plus Therapeutics has commenced Part B of the ReSPECT-LM Phase 1/2a trial for rhenium (186Re) obisbemeda, targeting leptomeningeal metastases. Initial findings from Part A demonstrate encouraging results, including survival data and a significant reduction in tumor cell counts in cerebrospinal fluid. The trial aims to establish a maximum tolerated dose while exploring multiple dosing options in collaboration with the FDA. The study is partially funded by a $17.6 million grant from the Cancer Prevention & Research Institute of Texas.
Read more →Plus Therapeutics, Inc. announced that its CEO, Dr. Marc Hedrick, will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023. The presentation will focus on the company's development of targeted radiotherapeutics for central nervous system cancers. Plus Therapeutics is advancing a pipeline aimed at improving outcomes for difficult-to-treat cancers, especially in recurrent glioblastoma and leptomeningeal metastases. Investors can arrange meetings with the company's management during the event, which will also be available for replay on their website.
Read more →Plus Therapeutics reported its second-quarter financial results and highlighted progress in clinical trials for leptomeningeal metastases and recurrent glioblastoma. Key developments include receiving FDA approval to move forward with Phase 1/Part B of the ReSPECT-LM trial and meeting objectives set forth in a significant grant. The company aims to leverage external funding to advance both clinical programs and enhance treatment options for these cancers. Financially, Plus Therapeutics reduced its operating expenses while maintaining various capital sources for ongoing activities.
Read more →Plus Therapeutics has reported positive preliminary data from the ReSPECT-LM Phase 1 trial, demonstrating safety and efficacy with a median overall survival of 10 months for patients with leptomeningeal metastases. The FDA has approved the continuation to Phase 1 Part B of the trial, indicating confidence in its progress. A total of 10 patients were treated, with no dose-limiting toxicities and most adverse effects being mild. The treatment showed significant tumor reduction in cerebrospinal fluid, suggesting potential clinical benefits.
Read more →The article discusses the use of cookies on a website, detailing the types of cookies used and their purposes. It emphasizes the importance of necessary cookies for website functionality and provides options for users to manage their cookie preferences. However, it lacks specific information regarding the Key Opinion Leaders Roundtable.
Read more →Plus Therapeutics, Inc. has announced a key opinion leader roundtable scheduled for August 11, 2023, to discuss new data from the ReSPECT-LM clinical trial of rhenium (186Re) obisbemeda. This clinical trial focuses on treating leptomeningeal metastases and will be presented at the 2023 SNO/ASCO CNS Cancer Conference. Notable speakers include leading medical professionals involved in the trial, highlighting the discussion's significance in advancing treatment options for central nervous system cancers.
Read more →Plus Therapeutics, Inc. will report its second quarter 2023 financial results on August 14, 2023. Following the announcement, the management team will host a conference call at 5:00 p.m. ET for a detailed discussion of the results and a corporate update. The company specializes in developing targeted radiotherapeutics for challenging cancers, showcasing its commitment to advancing cancer treatment. A live webcast of the call will be available for participants.
Read more →Plus Therapeutics, Inc. will present at the Canaccord Genuity 43rd Annual Growth Conference on August 9, 2023, in Boston, Massachusetts. The company is focused on developing targeted radiotherapeutics for central nervous system cancers. Interested investors can arrange meetings or access a webcast of the presentation on the company’s website. Plus Therapeutics is recognized for its innovative approach and has a strong pipeline including programs addressing recurrent glioblastoma and leptomeningeal metastases.
Read more →Plus Therapeutics, Inc. announced it will present new clinical data at the 2023 SNO/ASCO CNS Cancer Conference on August 10-12, 2023. The presentations will include findings from studies on their lead radiotherapeutic, rhenium (186Re) obisbemeda, addressing treatments for leptomeningeal metastases and recurrent glioblastoma. Additionally, details on the upcoming ReSPECT-PBC trial for childhood ependymoma and high-grade glioma will be shared. This opportunity reflects the company's ongoing commitment to advancing cancer therapeutics.
Read more →Plus Therapeutics has appointed Pius Maliakal as Vice President of Clinical Operations to enhance its clinical program. Dr. Maliakal will focus on advancing the company's key clinical trials, ReSPECT-GBM and ReSPECT-LM. He brings over 20 years of oncology experience, having previously led clinical development efforts at various pharmaceutical companies. This move is geared towards expediting the company's pipeline development aimed at treating central nervous system cancers.
Read more →Plus Therapeutics, Inc. announced that CEO Marc Hedrick will present at the 2nd Annual Targeted Radiopharmaceuticals Summit in Boston from July 25-27, 2023. The presentations will cover data from the ReSPECT-GBM study on rhenium (186Re) obisbemeda and outline the company's pipeline and scientific approaches. This summit provides a platform to engage with advancements in targeted radiotherapy for central nervous system cancers.
Read more →Plus Therapeutics, Inc. reported positive interim updates from its ReSPECT-GBM and ReSPECT-LM clinical trials at the SNMMI Annual Meeting. The trials, evaluating the safety and efficacy of rhenium (186Re) obisbemeda for recurrent glioblastoma and leptomeningeal metastases, found that higher absorbed radiation doses correlated with improved overall survival rates. Specifically, the median overall survival for patients receiving doses over 100 Gy was 17 months, notably better than the standard care. The trials will continue with further evaluations and dosing strategies planned for the future.
Read more →Plus Therapeutics, Inc. (PSTV), a clinical-stage pharmaceutical company, will participate in the 2023 Healthcare Virtual Conference hosted by Maxim Group LLC and M-Vest. CEO Marc Hedrick will partake in a fireside chat on June 21, 2023. Plus Therapeutics is advancing its pipeline focused on targeted radiotherapeutics for challenging central nervous system cancers, including recurrent glioblastoma and leptomeningeal metastases. The conference aims to enhance investor relations and provide updates on the company's progress and innovations.
Read more →Plus Therapeutics, a clinical-stage pharmaceutical company, announced its participation in the upcoming SNO Pediatric Conference and the SNMMI Annual Meeting. The events will take place from June 22-27, 2023, where Chief Medical Officer Norman LaFrance will present data from clinical studies on its lead radiotherapeutic, rhenium (186Re) obisbemeda, aimed at treating recurrent glioblastoma and leptomeningeal metastases. The company continues to advance its innovative therapies aimed at enhancing treatment outcomes for central nervous system cancers.
Read more →Plus Therapeutics, a clinical-stage pharmaceutical company, announced that its CEO, Marc Hedrick, will provide a comprehensive update on the company's activities during the 2023 Virtual June Investor Summit. The presentation will cover ongoing clinical and preclinical development programs focused on targeted radiotherapeutics for central nervous system cancers. The company has highlighted its strategic partnerships and leadership team as key assets in advancing its innovative treatments for conditions such as recurrent glioblastoma and leptomeningeal metastases.
Read more →Plus Therapeutics has announced positive topline results from an external control analysis for its recurrent glioblastoma treatment, rhenium (186Re) obisbemeda, in collaboration with Medidata. The analysis, accepted for presentation at the 2023 ASCO Annual Meeting, indicates comparable median overall survival times for patients treated with bevacizumab and those receiving convection-enhanced delivery. This data lends support to the use of a historical control arm in upcoming clinical trials, which may enhance trial efficiency and decrease costs. Plus Therapeutics continues to develop targeted radiotherapeutics for central nervous system cancers, aiming to improve clinical outcomes for patients.
Read more →Plus Therapeutics, Inc. announced that its CEO, Marc Hedrick, will present at the 2023 Virtual June Investor Summit on June 1, 2023. The company focuses on developing targeted radiotherapeutics for central nervous system cancers, and has a promising pipeline, particularly in recurrent glioblastoma and leptomeningeal metastases. Interested investors can arrange meetings during the conference or view the presentation via a webcast available on the company's website. Plus Therapeutics is recognized for its strategic partnerships that bolster its development and manufacturing capabilities.
Read more →Plus Therapeutics, Inc. has successfully regained compliance with Nasdaq listing requirements after its stock price remained above $1.00 for 10 consecutive business days. The notification from Nasdaq signifies that the matter is now closed, reflecting the company's improved financial position. Plus Therapeutics is renowned for its work in developing targeted radiotherapeutics aimed at treating central nervous system cancers.
Read more →Plus Therapeutics, Inc. announced that Dr. Norman LaFrance will present at the 'Know All Your Treatment Options 2023' virtual event organized by the EndBrainCancer Initiative. The presentation will focus on a novel targeted radiotherapeutic specifically developed for brain cancer, detailing the ReSPECT trials. The event will take place on May 19, 2023, and aims to enhance patient awareness of treatment options for brain cancer. Plus Therapeutics is focused on developing advanced therapies for central nervous system cancers.
Read more →Plus Therapeutics has expanded its collaboration with Piramal Pharma Solutions to produce additional drug product to support the growing demand for rhenium (186Re) obisbemeda. This partnership builds upon their existing agreement from 2021 and aims to bolster the supply chain for ongoing and planned clinical trials, particularly in the area of central nervous system cancers. The CEO of Plus Therapeutics expressed optimism about the momentum in clinical trial programs and future commercialization prospects.
Read more →Plus Therapeutics has reported its financial results for Q1 2023, highlighting significant progress in clinical trials, including the completion of Part A of the ReSPECT-LM trial and increased enrollment in the ReSPECT-GBM trials. The company holds a cash balance of $12.7 million and has secured substantial grant funding, indicating a solid financial foundation. However, the company also noted an increase in net loss and operating expenses compared to the same period last year, which could be a concern for future operations.
Read more →Plus Therapeutics has announced the completion of enrollment for the original three patients required for Cohort 8 of its ReSPECT-GBM Phase 1/2a trial, exploring the use of rhenium (186Re) obisbemeda in treating recurrent glioblastoma. The company has successfully treated 27 patients so far and received FDA designations for the treatment. This trial aims to provide insights into the therapy's safety and efficacy, with plans to share results later this year. Plus is also advancing a Phase 2b trial for different tumor sizes and has a retreatment option for previous patients.
Read more →Plus Therapeutics, Inc. announced that Chief Medical Officer Norman LaFrance will present at the Canaccord Genuity Horizons in Oncology Virtual Conference. The panel discussion will focus on emerging approaches to radiotherapy, with a specific emphasis on their initiatives alongside Y-mAbs Therapeutics. The event is scheduled for April 20, 2023, emphasizing Plus Therapeutics' commitment to advancing treatments for central nervous system cancers.
Read more →Plus Therapeutics has completed Phase 1/Part A of its ReSPECT-LM clinical trial investigating rhenium (186Re) obisbemeda for leptomeningeal metastases. The trial has rapidly enrolled patients, with no observed dose-limiting toxicities across the administered radiation doses. The company is set to discuss next steps with the U.S. FDA and intends to present data from the trial later in 2023. This clinical effort marks a significant step forward in providing treatment options for patients with this rare and often terminal condition.
Read more →Plus Therapeutics, Inc. announced that it will report its first quarter 2023 financial results on April 20, 2023. Following the results announcement, management will host a conference call and provide a corporate update. This event marks an important opportunity for shareholders and stakeholders to gain insights into the company's performance and pipeline developments in the field of targeted radiotherapeutics for cancers.
Read more →Plus Therapeutics has successfully treated the first patient in Cohort 8 of its ReSPECT-GBM Phase 1/2a trial, using its lead investigational drug, rhenium (186Re) obisbemeda, for recurrent glioblastoma (GBM). So far, 25 patients have been treated in the dose escalation phase with no dose-limiting toxicities noted. The company is also enrolling in the ReSPECT-GBM Phase 2 trial and plans to present data from both trials later in 2023. Additionally, the drug has received Orphan Drug and Fast Track designations from the FDA.
Read more →Plus Therapeutics has commenced treatment of the first patient in Cohort 3 of its ReSPECT-LM Phase 1/2a trial, targeting leptomeningeal metastases. The trial has previously demonstrated safety and efficacy, with encouraging results from earlier cohorts. Notably, there have been no observed dose-limiting toxicities with radiation doses administered so far. The FDA has granted Fast Track designation for the investigational treatment, indicating a streamlined development pathway.
Read more →Plus Therapeutics, Inc. reported its fourth quarter and full year 2022 financial results, highlighting key achievements in developing radiotherapeutics for CNS cancers. The company successfully initiated Phase 2 and Phase 1 clinical trials for recurrent glioblastoma and leptomeningeal metastases. They received a $17.6 million grant from CPRIT to support the development of their investigational drug. Despite a significant net loss for the year, Plus Therapeutics expects to maintain financial stability through grants and funding until 2025.
Read more →Plus Therapeutics, Inc. has announced that it will report its fourth quarter and full year 2022 financial results on February 23, 2023. Following the announcement, a conference call and webcast will be hosted by the management team to discuss the results and provide further updates about the company's activities. The event will be accessible to the public through a live webcast, and a replay will be available on their website for 90 days. Plus Therapeutics focuses on developing targeted radiotherapeutics for challenging cancers.
Read more →Plus Therapeutics has completed enrollment in Cohort 2 of its ReSPECT-LM Phase 1/2a trial, studying rhenium (186Re) obisbemeda for leptomeningeal metastases. Following a review by the Data and Safety Monitoring Board, the company anticipates initial data from the trial in H2 2023 and possible discussions with the FDA regarding dose expansion. The trial aims to find the maximum tolerated dose and assess safety and efficacy, with exciting early results reported in previous cohorts.
Read more →Plus Therapeutics has marked a significant milestone with the first patient dosed in the ReSPECT-GBM Phase 2b trial evaluating rhenium (186Re) obisbemeda for recurrent glioblastoma. The trial aims to assess the safety and efficacy of the treatment and is supported by the National Cancer Institute. Initial Phase 1/2a results suggested a positive correlation between radiation dose and overall survival, with expectations to confirm these findings in a broader patient population over the next 24 months. The trial is noteworthy as glioblastoma currently lacks effective treatment options for recurrence.
Read more →ReSPECT-GBM clinical trial of rhenium (186Re) obisbemeda in recurrent glioblastoma continues to demonstrate safety and overall survival correlates with radiation dose to tumor ReSPECT-GBM Phase 2 trial enrollment has begun Update on ReSPECT-LM clinical trial and first-in-child
Read more →Recurrent glioblastoma and leptomeningeal metastases data have been selected for oral presentations Pediatric brain cancer plans will be shared via poster session AUSTIN, Texas, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical
Read more →AUSTIN, Texas, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that the World Health Organi
Read more →Plus Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights Awarded $17.6 million Product Development Research grant by the Cancer Prevention & Research Institute of Texas (CPRIT) to fund 186RNL development for leptomeningeal metastases (LM) Completed
Read more →ReSPECT-LM Phase 1 clinical trial selected as TOP Trials Oral Presentation Treatment was well tolerated without dose limiting toxicities and all patients showed a decrease in spinal fluid tumor cell counts ReSPECT-GBM Phase 1 clinical data selected as Top-Rated Oral Presentatio
Read more →AUSTIN, Texas, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, announced today that Marc Hedrick, M.D., President and Chief
Read more →AUSTIN, Texas, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report third
Read more →AUSTIN, Texas, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that Dr. Andrew Brenner, M.D
Read more →AUSTIN, Texas, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it will present data from tw
Read more →Plus Therapeutics Executes $17.6 Million Award Contract with Cancer Prevention & Research Institute of Texas Initial CPRIT grant funds of $1.9 million to be disbursed to Company by October 31, 2022 CPRIT grant to support majority of 186RNL targeted therapeutic development cost
Read more →Phase 1 data indicates that direct administration of 186RNL targeted radiotherapeutic is safe in patients with recurrent glioblastoma Statistically significant overall survival benefit observed with 186RNL radiation doses over 100 Gray NIH-funded trial moving to Phase 2 to expl
Read more →AUSTIN, Texas, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, announced today that Marc Hedrick, M.D., President and Chie
Read more →NIH-funded ReSPECT-GBM Phase 2 trial to start in 2022 ReSPECT-GBM Phase 2 to focus on 186RNL dose expansion, safety and efficacy data to support future registrational trial AUSTIN, Texas, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stag
Read more →Plus Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights Completed enrollment of Cohort 1 in ReSPECT-LM Phase 1/2a dose escalation trial of 186RNL for Leptomeningeal Metastases On track to complete key manufacturing objectives for cGMP 186RNL to s
Read more →Plus Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights First patient dosed in ReSPECT-LM Phase 1/2a dose escalation trial of 186RNL for leptomeningeal metastases Closed in licensing transaction for novel targeted radioembolic technology for the t
Read more →Plus Therapeutics and Medidata Announce Expanded Clinical Trial Partnership Companies collaborate to design innovative registrational trial of 186RNL for recurrent glioblastoma Proprietary Synthetic Control Arm solution intended to enhance enrollment and reduce costs AUSTIN, T
Read more →Plus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights Expanded pipeline with recently licensed targeted interventional radiotherapeutics platform Announced positive interim data from ReSPECT-GBM Phase 1 clinical trial Management
Read more →Plus Therapeutics Significantly Expands Investigational Oncology Drug Pipeline Licenses targeted interventional radiotherapeutics platform Worldwide exclusive rights obtained for patents and next-generation technology to deliver targeted, precision radiotherapeutics for solid
Read more →Plus Therapeutics Announces Positive Interim Data from ReSPECT -GBM Phase 1 Clinical Trial at the 2021 Society for Neuro-Oncology Annual Meeting analysis shows Rhenium-186 NanoLiposome (186RNL) well-tolerated without dose-limiting toxicities Mean and median overall survival in
Read more →Plus Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights Management to host conference call today at 5:00 p.m. ET AUSTIN, Texas, October 21, 2021 - Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company deve
Read more →Plus Therapeutics Announces the Appointment of Industry Veteran, Norman LaFrance, M.D., as the Company s Chief Medical Officer AUSTIN, Texas, September 13, 2021 Plus Therapeutics, Inc. (Nasdaq: PSTV) (the Company ), a clinical-stage pharmaceutical company developing innovative
Read more →Plus Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights Management to host conference call today at 5:00 pm ET AUSTIN, Texas, July 22, 2021 - Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developi
Read more →Plus Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights - Management to host conference call today at 5:00 pm ET - AUSTIN, Texas, April 22, 2021 - Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company deve
Read more →Plus Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights - Positive interim data through cohort five for the ReSPECT Phase 1 clinical trial in recurrent glioblastoma, announced November 2020 - - Completed sixth dosing cohort in ReSPE
Read more →Plus Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights - Received FDA Orphan Drug and Fast Track designations for novel glioblastoma radiotherapy - - Management to host conference call today, Thursday, October 22nd, at 5:00 p.m. ET - AUSTIN, Tex
Read more →Plus Therapeutics Receives Fast Track Designation for Its Novel Glioblastoma Treatment AUSTIN, Texas, September 15, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), today announced that the U.S. Food and Drug Administration (FDA) has granted the C
Read more →Plus Therapeutics Reports Second Quarter 2020 Financial and Business Results AUSTIN, Texas, August 10, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), today announced financial and business results for its Second Quarter Fiscal Year 2020 ended Ju
Read more →Plus Therapeutics Reports First Quarter 2020 Financial and Business Results AUSTIN, Texas, May 14, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), today announced financial and business results for its first quarter fiscal year 2020 ended March
Read more →Plus Therapeutics Announces Closing of Agreement To License Novel Oncology Platform AUSTIN, Texas, May 11, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company", "Plus"), today announced the closing of its previously announced definitive agreement to lic
Read more →Plus Therapeutics Licenses Novel Oncology Platform, Expands Pipeline Multiple Clinical & Preclinical Candidates for Rare Cancers, Including a Novel Radiotherapeutic for Glioblastoma AUSTIN, Texas, March 30, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "
Read more →Plus Therapeutics Reports Fourth Quarter and Full Fiscal Year 2019 Financial and Business Results AUSTIN, Texas, March 30, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company", "Plus"), today announced financial and business results for its Fourth Quar
Read more →Plus Therapeutics Welcomes Two New Directors - Dr. Robert Lenk and Mr. Howard Clowes AUSTIN, Texas, March 12, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), today announced that Dr. Robert Lenk and Mr. Howard Clowes will join the Company's Boar
Read more →Plus Therapeutics Announces Changes to its Board of Directors AUSTIN, Texas, February 6, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), today announced that Greg B. Petersen has joined the Company's Board of Directors to serve as an independent
Read more →Plus Therapeutics Appoints Dr. An van Es-Johansson to Board of Directors AUSTIN, Texas, January 2, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), today announced that Dr. An van Es-Johansson has joined the Company's Board of Directors to serve a
Read more →Plus Therapeutics, Inc. Announces Pricing Of $15 Million Underwritten Public Offering AUSTIN, Texas, September 23, 2019 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:PSTV) (the "Company") today announced the pricing of an underwritten public offering (the "Offering") of 3,
Read more →Plus Therapeutics, Inc. ("we," "our" or the "Company") is filing this Exhibit 99.1 to our Current Report on Form 8-K (this "Exhibit") to revise and recast our historical consolidated financial statements and other information included in our Annual Report on Form 10-K for the fis
Read more →Cytori Will Become Plus Therapeutics, Inc. Plus Therapeutics Reflects A New Focus On Developing Innovative Drugs Austin, Texas, July 16, 2019 (GLOBE NEWSWIRE) - Cytori Therapeutics, Inc. (Nasdaq: CYTX) (the "company") announced yesterday a new direction and identity. Since the
Read more →Cytori Announces New Annual Stockholders Meeting Date for July 11 Annual Meeting Adjourned to Provide Additional Time to Obtain Approval of Key Business SAN DIEGO, CA - (GLOBE NEWSWIRE) Cytori Therapeutics, Inc. (Nasdaq: CYTX) today announced that it reconvened its annual meeti
Read more →Cytori Announces New Annual Stockholders Meeting Date for June 27 Annual Meeting Adjourned to Provide Additional Time to Obtain Approval of Key Business SAN DIEGO, CA - (GLOBE NEWSWIRE) Cytori Therapeutics, Inc. (Nasdaq: CYTX) today announced that it reconvened its annual meeti
Read more →Cytori to Present New Strategic Direction Company to Announce New Therapeutic Area Focus and Brand Identity Plans SAN DIEGO, June 13, 2019 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ: CYTX) "the Company" will provide a live webcast to discuss its continued transformat
Read more →Cytori Announces New Annual Stockholders Meeting Date for June 18 May 28 Meeting Adjourned to Provide Additional Time to Obtain Approval of Key Business SAN DIEGO, CA - (GLOBE NEWSWIRE) May 30, 2019 - Cytori Therapeutics, Inc. (Nasdaq: CYTX) today announced that it convened its
Read more →Cytori Therapeutics contact Gary Titus +1.858.458.0900 ir@cytori.com Cytori Reports Q1 2019 Business and Financial Results SAN DIEGO, May 14, 2019-Cytori Therapeutics (NASDAQ: CYTX) ("Cytori" or the "Company") today announced Q1 2019 financial results and provided updates on co
Read more →Cytori Reports Fourth Quarter and Full Year 2018 Business and Financial Results Strategic focus on building a leading oncology company / Lorem Vascular cell therapy transaction yields $4MM Letter of intent for ATI-0918 filed with EMEA SAN DIEGO, April 01, 2019-Cytori Therapeut
Read more →Cytori Therapeutics contact Tiago Girao +1.858.458.0900 ir@cytori.com Cytori Reports Q3 2018 Business and Financial Results SAN DIEGO, November 14, 2018-Cytori Therapeutics (NASDAQ: CYTX) ("Cytori" or the "Company") today announced Q3 2018 financial results and provided updates
Read more →Cytori Therapeutics contact Tiago Girao +1.858.458.0900 ir@cytori.com Cytori Reports Q2 2018 Business and Financial Results SAN DIEGO, August 14, 2018-Cytori Therapeutics (NASDAQ: CYTX) ("Cytori" or the "Company") today announced Q2 2018 financial results and provided updates o
Read more →Cytori Therapeutics contact Tiago Girao +1.858.458.0900 ir@cytori.com Cytori Reports Q1 2018 Business and Financial Results SAN DIEGO, May 10, 2018-Cytori Therapeutics (NASDAQ: CYTX) ("Cytori" or the "Company") today announced Q1 2018 financial results and provided updates on c
Read more →Cytori Therapeutics contact Tiago Girao +1.858.458.0900 ir@cytori.com Cytori Reports Fourth Quarter and Full Year 2017 Business and Financial Results SAN DIEGO, March 8, 2018-Cytori Therapeutics (NASDAQ: CYTX) ("Cytori" or the "Company") today announced its fourth quarter and y
Read more →Cytori Reports Third Quarter 2017 Business and Financial Results SAN DIEGO, November 9, 2017-Cytori Therapeutics (NASDAQ: CYTX) ("Cytori" or the "Company") today announced its third quarter 2017 financial results and provided updates on its corporate activity and clinical develo
Read more →Cytori Therapeutics contact Tiago Girao +1.858.458.0900 ir@cytori.com Cytori Reports Second Quarter 2017 Business and Financial Results SAN DIEGO, August 10, 2017-Cytori Therapeutics (NASDAQ: CYTX) ("Cytori" or the "Company") today announced its second quarter 2017 financial re
Read more →Cytori Therapeutics contact Tiago Girao +1.858.458.0900 ir@cytori.com Cytori Reports First Quarter 2017 Business and Financial Results SAN DIEGO, May 11, 2017-Cytori Therapeutics (NASDAQ: CYTX) ("Cytori" or the "Company") today announced its first quarter 2017 financial results
Read more →Cytori Announces Proposed Public Offering of Common Stock SAN DIEGO, April 10, 2017 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. ( Cytori or the Company ) (NASDAQ: CYTX) announced today that it intends to offer and sell shares of its common stock in an underwritten public offe
Read more →Cytori Therapeutics contact Tiago Girao +1.858.458.0900 ir@cytori.com Cytori Reports Fourth Quarter and Full Year 2016 Business and Financial Results SAN DIEGO, March 23, 2017-Cytori Therapeutics (NASDAQ: CYTX) ("Cytori" or the "Company") today announced its fourth quarter and
Read more →Enhancing lives through novel cell therapies Cytori Therapeutics Update | January 2017 NASDAQ: CYTX EXHIBIT 99.1 Forward Looking Statements and Disclaimers 33% 15% 11% 22% 19% OTHER USA EU JAPAN ASIA-PACIFIC This presentation contains certain forward-looking statements' about Cy
Read more →Cytori Therapeutics contact Tiago Girao +1.858.458.0900 ir@cytori.com Cytori Reports Third Quarter 2016 Business and Financial Results SAN DIEGO, November 9, 2016-Cytori Therapeutics (NASDAQ: CYTX) ("Cytori" or the "Company") today announced its third quarter financial results
Read more →BARDA Increases Contract Option with Cytori to Advance Countermeasure Clinical Trial Increased Option Value to $16.6 Million for Burn Wound Treatment SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics (NASDAQ: CYTX) (the "Company") today announced that the Company and Biomedical
Read more →Cytori Announces Expiration of Rights Offering and Estimated Gross Proceeds of $17.1 Million SAN DIEGO - (BUSINESS WIRE) Cytori Therapeutics, Inc. ("Cytori" or the "Company") (NASDAQ: CYTX) announced today that the subscription period for its previously announced rights offering
Read more →Cytori Extends Rights Offering Subscription Period to Friday June 10 and Adjusts Unit Pricing Investors Invited for a Update Call on Monday June 6 SAN DIEGO - (BUSINESS WIRE) Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today it has extended the subscription period and ad
Read more →Cytori Announces Commencement of Subscription Period for Previously Announced Rights Offering SAN DIEGO - (BUSINESS WIRE) Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today it has commenced the subscription period for its previously announced rights offering of up to 6,896
Read more →CYTORI THERAPEUTICS CONTACT Tiago Girao +1.858.458.0900 ir@cytori.com Cytori Reports Fourth Quarter and Full Year 2015 Business and Financial Results SAN DIEGO, March 03, 2016-Cytori Therapeutics (NASDAQ: CYTX) (Cytori or the "Company") today announced its fourth quarter and ye
Read more →Cytori Therapeutics NASDAQ: CYTX Enhancing lives through novel cell therapies Biotech Showcase I January 2016 Forward Looking Statements and Disclaimers 33% 15% 11% 22% 19% OTHER USA EU JAPAN ASIA-PACIFIC This presentation contains certain forward-looking statements' about Cytor
Read more →Cytori Amends Corporate Warrant Agreements Simplifying Capital Structure and Updates on 2015 Operating Cash Burn Guidance Cytori Therapeutics, Inc. (CYTX) (the Company ) today announced that it has entered into definitive agreements with certain holders (the Consenting Holders
Read more →CYTORI THERAPEUTICS CONTACT Tiago Girao +1.858.458.0900 ir@cytori.com Cytori Reports Third Quarter 2015 Business and Financial Results SAN DIEGO, November 05, 2015-Cytori Therapeutics (NASDAQ: CYTX) today announced its third quarter financial results and provided updates on its
Read more →Cytori Restructures its Debt to a $17.7 Million Term Loan SAN DIEGO, CA -- Cytori Therapeutics (NASDAQ: CYTX) entered into a four year, $17.7 million term loan with Oxford Finance LLC. The loan provides for an interest-only payment period of at least 12-months with the potential
Read more →Cytori Prices Registered Direct Offering Providing for up to $25 million in Equity Financing SAN DIEGO Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced the pricing of a registered direct public offering of Units, with each Unit consisting of one share of our common stoc
Read more →Cytori Provides Twelve Month Data Update on Scleradec-I Trial SAN DIEGO Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today preliminary 12 month follow-up data from the 12 patient investigator initiated Scleradec-I clinical trial conducted by Prof. B. Granel and Prof. G. M
Read more →Cytori TherapeuticsNASDAQ: CYTXCorporate UpdateMarch 2015 NASDAQ: CYTX Restoring Lives * Forward Looking Statements This presentation contains certain forward-looking statements' about Cytori Therapeutics, Inc. All statements, other than statements of historical fact, that addre
Read more →Cytori Therapeutics NASDAQ: CYTX Investor Update January 2015 NASDAQ: CYTX Restoring Lives * Forward-looking Statements This presentation contains certain forward-looking statements' about Cytori Therapeutics, Inc. All statements, other than statements of historical fact, that a
Read more →CYTORI THERAPEUTICS CONTACT mmccormick@cytori.com Therapeutics to Raise $10 Million In Registered Direct Offering SAN DIEGO, May 30, 2014 Cytori Therapeutics, Inc. (CYTX) entered into subscription agreements with certain institutional investors to raise approximately $10 mill
Read more →CYTORI THERAPEUTICS CONTACT Megan McCormick +1.858.875.5279 mmccormick@cytori.com Cytori Announces Senior Management Changes SAN DIEGO, April 2, 2014 - Cytori Therapeutics (NASDAQ: CYTX) today announced that Christopher Calhoun, Chief Executive Officer and Director of Cytori Th
Read more →CYTORI THERAPEUTICS CONTACT Megan McCormick +1.858.875.5279 mmccormick@cytori.com Cytori Reports Fourth Quarter and Full Year 2013 Business and Financial Results SAN DIEGO, March 11, 2014-Cytori Therapeutics (NASDAQ: CYTX) reports its fourth quarter and year end 2013 business a
Read more →Cytori Reports 2012 Business and Financial Results; Provides Outlook for 2013 - U.S. ATHENA trial on track for mid-2013 completion of enrollment with 1st data in 1H 2014 - - BARDA: Contract activities underway - - Achieved $9.1 million in product and contract revenue for 2012
Read more →Intravase Approval Opens Vascular Market for Cytori; Cytori Receives CE Mark for Specialized Cell Therapy Reagent for Intravascular Delivery SAN DIEGO-Cytori Therapeutics (NASDAQ: CYTX) has received a CE Mark in Europe for Intravase , a reagent intended to be used with Cytori's
Read more →Cytori Reports Third Quarter Business Update and Financial Results San Diego, CA -- Cytori Therapeutics (NASDAQ: CYTX) today is reporting its third quarter 2011 business update and financial results. Product revenues for the third quarter of 2011 increased to $2.1 million, comp
Read more →Cytori Reports Second Quarter Results; Provides Commercial and Product Pipeline Update SAN DIEGO - Cytori Therapeutics, Inc. (NASDAQ: CYTX) provides a quarterly update on its development pipeline and reports financial results for the second quarter of 2011. "Our focus is on adv
Read more →Cytori Provides Update on Product Pipeline Developments and Reports First Quarter Results San Diego - Cytori Therapeutics, Inc. (NASDAQ: CYTX) provides a quarterly update on its development pipeline and reports financial results for the first quarter of 2011. Cytori is developi
Read more →Cytori Grows Product Revenues 41% Year-Over-Year, Advances Cardiac Device Product Pipeline SAN DIEGO--Cytori Therapeutics (NASDAQ:CYTX) grew product sales 41% and made substantial progress in advancing its cardiovascular device product pipeline during 2010. An overview of the Co
Read more →